Leiter Lawrence A
St Michael's Hospital, University of Toronto, 61 Queen St East #6121, Toronto, Ont., Canada M5C 2T2.
Diabetes Res Clin Pract. 2005 Jun;68 Suppl 2:S3-14. doi: 10.1016/j.diabres.2005.03.015. Epub 2005 Apr 14.
The role of hyperglycemia in the development of microvascular complications of diabetes, such as nephropathy, retinopathy and neuropathy, has been well documented. Evidence is accumulating to support the concept that dyslipidemia can also contribute to the development of these complications. Lipid-lowering agents, such as statins, have been shown to prevent cardiovascular events in patients with diabetes. However, in addition to preventing macrovascular diseases, statins may also be able to retard the progression of microvascular complications of diabetes. Indeed, in addition to reducing lipid levels, these agents can improve endothelial function and reduce oxidative stress, which can improve microvascular function. These findings would provide further support for the use of lipid-lowering agents in patients with diabetes.
高血糖在糖尿病微血管并发症(如肾病、视网膜病变和神经病变)发生发展中的作用已得到充分证实。越来越多的证据支持血脂异常也可促使这些并发症发生的观点。他汀类等降脂药物已被证明可预防糖尿病患者发生心血管事件。然而,除预防大血管疾病外,他汀类药物或许还能够延缓糖尿病微血管并发症的进展。实际上,除降低血脂水平外,这些药物还可改善内皮功能并减轻氧化应激,进而改善微血管功能。这些发现将为糖尿病患者使用降脂药物提供进一步的支持。